Key Points
- Insider sale: Apogee Therapeutics insider Carl Dambkowski sold 5,500 shares on June 3 at an average price of $78.71, totaling about $432,905. The sale was made under a pre-arranged Rule 10b5-1 plan, and his holdings fell 2.6%.
- Stock and earnings update: APGE shares were down 4.4% and opened at $86.92, near their 52-week high of $95.32. The company recently reported quarterly EPS of ($1.06), slightly better than expected.
- Wall Street outlook: Analysts remain broadly constructive, with a consensus rating of Moderate Buy and an average price target of $113.63. Recent firms including BTIG, Citi, and Canaccord raised or reiterated positive targets, though Weiss Ratings maintained a sell rating.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $78.71, for a total transaction of $432,905.00. Following the completion of the transaction, the insider directly owned 205,648 shares of the company's stock, valued at $16,186,554.08. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, May 6th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $84.14, for a total transaction of $462,770.00.
- On Wednesday, April 1st, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $84.84, for a total transaction of $466,620.00.
Apogee Therapeutics Stock Down 4.4%
Shares of APGE stock opened at $86.92 on Friday. Apogee Therapeutics Inc. has a 52 week low of $34.34 and a 52 week high of $95.32. The stock has a market capitalization of $5.38 billion, a PE ratio of -20.07 and a beta of 0.62. The firm has a 50 day moving average of $83.96 and a two-hundred day moving average of $76.58.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.01. Analysts expect that Apogee Therapeutics Inc. will post -4.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its stake in Apogee Therapeutics by 0.5% in the fourth quarter. Wellington Management Group LLP now owns 4,746,585 shares of the company's stock valued at $358,272,000 after purchasing an additional 22,884 shares during the period. Vanguard Group Inc. increased its stake in Apogee Therapeutics by 27.3% in the fourth quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company's stock valued at $215,709,000 after purchasing an additional 612,193 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in Apogee Therapeutics by 189,522.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company's stock valued at $206,246,000 after purchasing an additional 2,731,015 shares during the period. Janus Henderson Group PLC increased its stake in Apogee Therapeutics by 14.4% in the first quarter. Janus Henderson Group PLC now owns 2,360,596 shares of the company's stock valued at $198,809,000 after purchasing an additional 297,992 shares during the period. Finally, Perceptive Advisors LLC lifted its holdings in shares of Apogee Therapeutics by 72.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company's stock worth $175,918,000 after purchasing an additional 978,662 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have recently issued reports on APGE. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Apogee Therapeutics in a research report on Monday, April 20th. BTIG Research reaffirmed a "buy" rating and set a $137.00 price objective on shares of Apogee Therapeutics in a research report on Wednesday, May 27th. Citigroup lifted their price objective on shares of Apogee Therapeutics from $95.00 to $125.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. Canaccord Genuity Group lifted their price objective on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. Finally, The Goldman Sachs Group set a $89.00 price objective on shares of Apogee Therapeutics in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $113.63.
Get Our Latest Stock Report on Apogee Therapeutics
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
